Keros Therapeutics Third Quarter 2024 Earnings US1.41 loss per share
KROS Stock | USD 18.00 1.42 7.31% |
Slightly above 53% of Keros Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Keros Therapeutics suggests that many traders are impartial. Keros Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Keros Therapeutics' earnings reports, geopolitical events, and overall market trends.
Keros |
Keros Therapeutics Third Quarter 2024 Results Key Financial Results Net loss US53.0m loss widened by...
Read at finance.yahoo.com
Keros Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Keros Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Keros Therapeutics Fundamental Analysis
We analyze Keros Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Keros Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Keros Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Keros Therapeutics stock to make a market-neutral strategy. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics with similar companies.
Peers
Keros Therapeutics Related Equities
BOLT | Bolt Biotherapeutics | 2.88 | ||||
IDYA | Ideaya Biosciences | 2.35 | ||||
HRMY | Harmony Biosciences | 1.72 | ||||
AVTE | Aerovate Therapeutics | 1.56 | ||||
ANAB | AnaptysBio | 1.56 | ||||
SNDX | Syndax Pharmaceuticals | 0.15 | ||||
ERAS | Erasca | 0.38 | ||||
FENC | Fennec Pharmaceuticals | 0.82 | ||||
KZR | Kezar Life | 1.23 | ||||
MLYS | Mineralys Therapeutics, | 2.43 | ||||
GLUE | Monte Rosa | 2.74 | ||||
MGTX | MeiraGTx Holdings | 2.81 | ||||
JANX | Janux Therapeutics | 3.17 | ||||
LRMR | Larimar Therapeutics | 3.70 | ||||
SRZN | Surrozen | 4.80 | ||||
EWTX | Edgewise Therapeutics | 5.93 | ||||
REPL | Replimune | 5.93 | ||||
IPSC | Century Therapeutics | 5.98 |
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.